March 30, 2021
Allied BioScience is growing significantly as the innovative biotech firm commits to expanding regulatory approvals for the use of SurfaceWise2™ nationally and abroad to meet demand while diversifying the lineup of products beyond antimicrobial surface coatings.
As global demand for SurfaceWise2 continues to expand, the company has strategic partnerships in Canada, Germany, Australia, India and the United Arab Emirates, with more in the pipeline. Spanning industries including transportation, healthcare, fitness and retail, leading partners in these countries plan to distribute and apply the surface coating.
“Allied BioScience has been committed to reducing the global burden of infectious disease for over a decade, but we’re especially proud of the innovation over the past year,” said Michael Ruley, CEO of Allied BioScience. “We remain focused on our mission as we expand globally, providing SurfaceWise2 to nations as part of the fight against COVID-19 and other viruses, and continue to diversify our products to keep our friends and families safer in new ways.”
Following initial emergency use authorization for SurfaceWise2 in the State of Texas by the Environmental Protection Agency, the company continues to work closely with the agency to increase access to the revolutionary residual COVID-19-fighting solution. The EPA recently announced the expansion of this authorization for the states of Oklahoma and Arkansas, as well as an approved extended residual efficacy of 30 days. Broad, national approval is expected in the coming months.
The company recently relocated its Plano headquarters to a new office space with nearly double its previous square footage to account for anticipated team expansion and plans to expand offerings outside of its flagship surface coatings in 2021.
